Millendo Therapeutics, Inc. (MLND) |
| 1.06 -0.06 (-5.36%) 06-28 00:00 |
| Open: | 1.12 |
| High: | 1.13 |
| Low: | 1.06 |
| Volume: | 1,912,625 |
| Market Cap: | 11(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 85.01 |
| Resistance 1: | 72.78 |
| Pivot price: | 62.43 |
| Support 1: | 60.27 |
| Support 2: | 52.54 |
| 52w High: | 41.549793 |
| 52w Low: | 1.06 |
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Financials
| EPS | -2.240 |
| Book Value | 7.030 |
| PEG Ratio | 0.00 |
| Gross Profit | 5.118 |
| Profit Margin (%) | -22.43 |
| Operating Margin (%) | -3.50 |
| Return on Assets (ttm) | -4.5 |
| Return on Equity (ttm) | -29.4 |
Company news
Thu, 06 Apr 2023
John G Simon Net Worth (2026) - GuruFocus
Tue, 20 Dec 2022
Julia C. Owens Net Worth (2026) - GuruFocus
Wed, 16 Nov 2022
Stephen Kraus Net Worth (2026) - GuruFocus
Sun, 06 Dec 2020
Millendo Therapeutics Stock Price Forecast. Should You Buy MLND? - StockInvest.us
Thu, 24 Sep 2020
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist - Business Wire
Tue, 09 Jun 2020
Dwindling Prader-Willi Syndrome Drug Development Landscape And Hopeful Therapies - RTTNews
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
